구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | PD-1 antibody |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Locally Recurrent Rectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway |
MoA Biomarker | PD-1⁺ TCF1⁺) T cells, as well as CD40 high |
PK/PD Half-life | 35.14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Discovery of Thiazolo[5,4-c]pyridine Derivatives as Novel Hematopoietic Progenitor Kinase 1 Inhibitors for Tumor Immunotherapy.. Hematopoietic progenitor kinase 1 (HPK1) functions as an intracellular negative regulator of T-cell receptor signaling, and its inhibition has emerged as a promising strategy to counteract T-cell exhaustion and potentiate antitumor immunity. Through rational structural o… |
Clinical Safety signal | Discovery of Thiazolo[5,4-c]pyridine Derivatives as Novel Hematopoietic Progenitor Kinase 1 Inhibitors for Tumor Immunotherapy.. Hematopoietic progenitor kinase 1 (HPK1) functions as an intracellular negative regulator of T-cell receptor signaling, and its inhibition has emerged as a promising strategy to counteract T-cell exhaustion and potentiate antitumor immunity. Through rational structural o… |
Clinical Selected reported efficacy | ORR 56.1% |
Clinical Reported ORR | 56.1% |
Clinical Reported PFS | 7.9 |
Clinical Reported OS | 13.1 |
Clinical Result source | ClinicalTrials.gov NCT02289209 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02289209 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | PD-1 antibody |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Locally Recurrent Rectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | target for cancer immunotherapy due to its negatively regulatory effect on the STING pathway |
MoA Biomarker | PD-1⁺ TCF1⁺) T cells, as well as CD40 high |
PK/PD Half-life | 35.14 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Discovery of Thiazolo[5,4-c]pyridine Derivatives as Novel Hematopoietic Progenitor Kinase 1 Inhibitors for Tumor Immunotherapy.. Hematopoietic progenitor kinase 1 (HPK1) functions as an intracellular negative regulator of T-cell receptor signaling, and its inhibition has emerged as a promising strategy to counteract T-cell exhaustion and potentiate antitumor immunity. Through rational structural o… |
Clinical Safety signal | Discovery of Thiazolo[5,4-c]pyridine Derivatives as Novel Hematopoietic Progenitor Kinase 1 Inhibitors for Tumor Immunotherapy.. Hematopoietic progenitor kinase 1 (HPK1) functions as an intracellular negative regulator of T-cell receptor signaling, and its inhibition has emerged as a promising strategy to counteract T-cell exhaustion and potentiate antitumor immunity. Through rational structural o… |
Clinical Selected reported efficacy | ORR 56.1% |
Clinical Reported ORR | 56.1% |
Clinical Reported PFS | 7.9 |
Clinical Reported OS | 13.1 |
Clinical Result source | ClinicalTrials.gov NCT02289209 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02289209 |
추천 비교
추천 비교